Evidence map›Paper›PMID 30321236›Full record

ArticlePloS one2018

Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: Estimates using the Spectrum-STI model, 1990-2017.

Ranmini S Kularatne, Ronelle Niit, Jane Rowley, Tendesayi Kufa-Chakezha, Remco P H Peters, Melanie M Taylor, Leigh F Johnson, Eline L Korenromp

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.

  1. Frontiers in microbiology · 2024
    Pooled it
  2. Trial
  3. Trial
  4. The Global Syphilis Epidemic: Turning the Tide.Sexually transmitted diseases · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Investigating causes of the high prevalence of sexually transmitted infections in Du Noon.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2024
    Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Ranmini S KularatneCentre for HIV & STI, National Institute for Communicable Diseases, Johannesburg, South Africa.
Ronelle NiitHealth Information Systems Programme, Pretoria, South Africa.
Jane RowleyIndependent consultant, London, United Kingdom.
Tendesayi Kufa-ChakezhaCentre for HIV & STI, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0002-9797-616X
Remco P H PetersAnova Health Institute, Johannesburg, South Africa.ORCID 0000-0003-2124-7275
Melanie M TaylorWorld Health Organization, Department of Reproductive Health and Research, Geneva, Switzerland.
Leigh F JohnsonUniversity of Cape Town, Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa.
Eline L KorenrompAvenir Health, Geneva, Switzerland.ORCID 0000-0002-5301-8461
Anova Health Institute · ZACenters for Disease Control and Prevention · USHealth Systems Trust · ZANational Institute for Communicable DiseasesUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZA

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectivesTo estimate trends in prevalence and incidence of syphilis, gonorrhea and chlamydia in adult men and women in South Africa.

methodsThe Spectrum-STI tool estimated trends in prevalence and incidence of active syphilis, gonorrhea and chlamydia, fitting South African prevalence data. Results were used, alongside programmatic surveillance data, to estimate trends in incident gonorrhea cases resistant to first-line treatment, and the reporting gap of symptomatic male gonorrhea and chlamydia cases treated but not reported as cases of urethritis syndrome.

resultsIn 2017 adult (15-49 years) the estimated female and male prevalences for syphilis were 0.50% (95% CI: 0.32-0.80%) and 0.97% (0.19-2.28%), for gonorrhea 6.6% (3.8-10.8%) and 3.5% (1.7-6.1%), and for chlamydia 14.7% (9.9-21%) and 6.0% (3.8-10.4%), respectively. Between 1990 and 2017 the estimated prevalence of syphilis declined steadily in women and men, probably in part reflecting improved treatment coverage. For gonorrhea and chlamydia, estimated prevalence and incidence showed no consistent time trend in either women or men. Despite growing annual numbers of gonorrhea cases - reflecting population growth - the estimated number of first line treatment-resistant gonorrhea cases did not increase between 2008 and 2017, owing to changes in first-line antimicrobial treatment regimens for gonorrhea in 2008 and 2014/5. Case reporting completeness among treated male urethritis syndrome episodes was estimated at 10-28% in 2017.

conclusionSouth Africa continues to suffer a high STI burden. Improvements in access and quality of maternal, STI and HIV health care services likely contributed to the decline in syphilis prevalence. The lack of any decline in gonorrhea and chlamydia prevalence highlights the need to enhance STI services beyond clinic-based syndromic case management, to reinvigorate primary STI and HIV prevention and, especially for women, to screen for asymptomatic infections.

Indexed as

AdolescentAdultChlamydia InfectionsDrug Resistance, BacterialEpidemiologyFemaleGonorrheaHumansIncidenceMaleMiddle AgedPrevalenceSexually Transmitted DiseasesSouth AfricaSyphilisUrethritis

Identifiers

PMID30321236
PMCPMC6188893
OpenAlexW2897223790

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.